Actor Darshan's wife asks police to warn him against 'bad' conduct

Mangaluru, June 28: Three fresh deaths in last 24 hours have taken the total number of covid-19 deaths in Dakshina Kannada district to 13.

While a 31-year-old youth from Idya in Surathkal and a 57-year-old woman from Bantwal passed away last night, a 52-year-old woman from Jokatte breathed her last today. 

The youth from Suratkal breathed his last in Wenlok. The woman from Bantwal’s Loretto Padav village was unwell for last 1 year. She was tested positive three days ago and passed away at a private hospital. 

The woman from Jokatte was reportedly suffering from tuberculosis. On June 26, she was admitted to a private hospital in the city, where she was tested coronavirus positive.

As per the district health bulletin on Saturday June 27 evening, a total of 12,919 samples have been sent for tests till date, out of which 12,198 have turned out negative, and 576 positive, including 10 persons from other districts. 

Out of these, 148 are currently active. As many as 416 persons have recovered and been discharged.

Mangaluru, Apr 25: The Mangalore Refinery and Petrochemicals Limited (MRPL) has extended vital assistance to hundreds of migrant workers, destitute and needy families during the COVID-19 crisis through its CSR fund.

The lockdown has left thousands of people including migrant workers and destitute in the district, in the lurch. MRPL, using its corporate social responsibility fund through the Dakshina Kannada district administration, has sponsored 50,000 kg rice for the benefit of these needy citizens, a company release here said.

MRPL also donated grocery kits comprising boiled rice, dal, rava, sugar and tea to the needy families in the district, it said.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.